From October 22 to 25, we had the privilege of participating in the XIII Latin American Congress of Inborn Errors of Metabolism and Neonatal Screening (SLEIMPN) in Punta del Este, Uruguay. This outstanding event brought together experts from across the region to address key topics in the field of rare diseases
SLEIMPN 2024 was much more than a review of scientific advancements; it was an opportunity to reflect on the future of healthcare and the strategies needed to overcome current challenges. At Innovative Medicines Group (IMG), we understand that interdisciplinary and regional collaboration is essential to creating a lasting impact on the lives of patients, especially those affected by rare diseases. Therefore, renewing our participation in the Congress was a key priority for our year.
Our presence at SLEIMPN 2024 reaffirmed our commitment to excellence, innovation, and the creation of a more equitable and accessible healthcare system for individuals with rare diseases.
Our participation was highlighted by two key initiatives that yielded extremely positive results. The first was the creation of a booth that not only served as a consultation space but was also open to welcoming others interested in sharing ideas, experiences, and concerns. Fortunately, the booth became a central meeting point for various discussions and meetings, standing out as the most prominent space in the sector.
The second key initiative was our role as sponsors, proudly partnering with Immedica, of the Symposium on Arginase Deficiency, one of the most significant moments of SLEIMPN. This symposium brought together international experts in the field of Inborn Errors of Metabolism, with a particular focus on Urea Cycle Disorders. With an excellent turnout, the symposium provided a unique opportunity for learning and exchange.
Dr. Marshall Summar played a central role in the symposium. His contribution was crucial in moderating the session and sharing not only his extensive experience but also his sharp insights on recent advances in the diagnosis and treatment of Urea Cycle Disorders, as well as unmet needs in this field.
The symposium also featured invaluable contributions from Dr. Carolina Fischinger Moura de Souza and Dr. Mattias Rudebeck.
Dr. Fischinger Moura de Souza presented clinical cases of Arginase Deficiency, clearly illustrating the presentation and clinical manifestations of this condition. This practical perspective was vital, as the low incidence of the disease makes its diagnosis and management an ongoing challenge.
Dr. Rudebeck, the principal investigator of the clinical trial on pegzilarginase, provided a comprehensive overview of this emerging enzyme therapy. He highlighted the demonstrated benefits of pegzilarginase as a promising option for treating patients with Arginase Deficiency.
Thanks to their tremendous generosity, some congress attendees had the opportunity to consult and discuss their questions on patient management. We are incredibly proud to have provided this exclusive opportunity, allowing participants to deepen their understanding of key topics and receive direct guidance.
The SLEIMPN 2024 Congress was not only a space for technical learning but also an opportunity to strengthen professional relationships. Social activities such as the Gala Dinner and networking events provided opportunities to forge closer ties among professionals from various disciplines and countries. IMG leveraged these moments to expand its network and form strategic alliances with other leading institutions in the healthcare sector, closing a year of hard work with highly positive results and looking ahead to what lies in store for 2025.
